These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7940738)

  • 1. Rat interleukin-2 immunoglobulin M fusion proteins are cytotoxic in vitro for cells expressing the IL-2 receptor and can abolish cell-mediated immunity in vivo.
    Bogers WM; Lang F; Parker KE; Le Mauff B; Anegon I; Jacques Y; Soulillou JP
    Transplantation; 1994 Oct; 58(8):932-9. PubMed ID: 7940738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor.
    Vié H; Gauthier T; Breathnach R; Bonneville M; Godard A; Dietrich J; Karam G; Gesnel MC; Peyrat MA; Jacques Y; Soulillou JP
    Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11337-41. PubMed ID: 1454817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo.
    Kelley VE; Bacha P; Pankewycz O; Nichols JC; Murphy JR; Strom TB
    Proc Natl Acad Sci U S A; 1988 Jun; 85(11):3980-4. PubMed ID: 3131768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant IL 2 but not recombinant interferon-gamma stimulates both proliferation and IgM secretion in a Ly-1+ clone of neoplastic murine B cells (BCL1).
    Brooks KH; Vitetta ES
    J Immunol; 1986 Nov; 137(10):3205-10. PubMed ID: 2945863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric interleukin 2 receptor alpha chain antibody derivatives with fused mu and gamma chains permit improved recruitment of effector functions.
    Schäffner M; François C; Kaluza B; Hock H; Jacques Y; Weidle UH
    Mol Immunol; 1995 Jan; 32(1):9-20. PubMed ID: 7870061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cluster-function relationship of rat-antimouse P55 IL-2 receptor monoclonal antibodies. In vitro studies of the CTL-L2 mouse cell line and in vivo studies in a delayed-type hypersensitivity model in mice.
    Dantal J; Jacques Y; Soulillou JP
    Transplantation; 1991 Jul; 52(1):110-5. PubMed ID: 1858138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice.
    Zheng XX; Steele AW; Hancock WW; Kawamoto K; Li XC; Nickerson PW; Li Y; Tian Y; Strom TB
    J Immunol; 1999 Oct; 163(7):4041-8. PubMed ID: 10491008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An IL-2-toxin, DAB389IL-2, inhibits delayed-type hypersensitivity but enhances IgE antibody production.
    Pullerits T; Lundin S; Dahlgren U; Telemo E; Hanson LA; Lötvall J
    J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):843-9. PubMed ID: 10329818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of anti-interleukin 2 receptor and anti-L3T4 antibodies on delayed type hypersensitivity: the role of complement and epitope.
    Kelley VE; Gaulton GN; Strom TB
    J Immunol; 1987 May; 138(9):2771-5. PubMed ID: 3106488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An interleukin-2-IgG-Fas ligand fusion protein suppresses delayed-type hypersensitivity in mice by triggering apoptosis in activated T cells as a novel strategy for immunosuppression.
    Bulfone-Paus S; Rückert R; Krause H; von Bernuth H; Notter M; Pohl T; Tran TH; Paus R; Kunzendorf U
    Transplantation; 2000 Apr; 69(7):1386-91. PubMed ID: 10798759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A soluble 'anchorminus' interleukin 2 receptor suppresses in vitro interleukin 2-mediated immune responses.
    Kondo N; Kondo S; Shimizu A; Honjo T; Hamuro J
    Immunol Lett; 1988 Dec; 19(4):299-307. PubMed ID: 2977379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.
    Bamford RN; Grant AJ; Burton JD; Peters C; Kurys G; Goldman CK; Brennan J; Roessler E; Waldmann TA
    Proc Natl Acad Sci U S A; 1994 May; 91(11):4940-4. PubMed ID: 8197161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R.
    Voss SD; Sondel PM; Robb RJ
    J Exp Med; 1992 Aug; 176(2):531-41. PubMed ID: 1500859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconstitution of the intermediate-affinity interleukin-2 receptor by cell fusion.
    Kuida K; Tanaka T; Kitamura F; Toyama-Sorimachi N; Miyasaka M
    Int Immunol; 1992 Oct; 4(10):1123-8. PubMed ID: 1489730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic efficacy of an anti-IL-2 receptor monoclonal antibody correlates with an increase in serum soluble IL-2 receptor levels.
    Volk HD; Josimovic-Alasevic O; Gross M; Diamantstein T
    Clin Exp Immunol; 1989 Apr; 76(1):121-5. PubMed ID: 2786777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells.
    Nakarai T; Robertson MJ; Streuli M; Wu Z; Ciardelli TL; Smith KA; Ritz J
    J Exp Med; 1994 Jul; 180(1):241-51. PubMed ID: 8006584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine and anti-interleukin 2 receptor monoclonal antibody therapy suppress accelerated rejection of rat cardiac allografts through different effector mechanisms.
    Hancock WW; DiStefano R; Braun P; Schweizer RT; Tilney NL; Kupiec-Weglinski JW
    Transplantation; 1990 Feb; 49(2):416-21. PubMed ID: 2106180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redirecting effector T cells through their IL-2 receptors.
    Lustgarten J; Marks J; Sherman LA
    J Immunol; 1999 Jan; 162(1):359-65. PubMed ID: 9886407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells.
    Tanaka T; Tsudo M; Karasuyama H; Kitamura F; Kono T; Hatakeyama M; Taniguchi T; Miyasaka M
    J Immunol; 1991 Oct; 147(7):2222-8. PubMed ID: 1918958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.